These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15040625)

  • 1. Safety concerns regarding ephedrine-type alkaloid-containing dietary supplements.
    Miller SC
    Mil Med; 2004 Feb; 169(2):87-93. PubMed ID: 15040625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis.
    Shekelle PG; Hardy ML; Morton SC; Maglione M; Mojica WA; Suttorp MJ; Rhodes SL; Jungvig L; Gagné J
    JAMA; 2003 Mar; 289(12):1537-45. PubMed ID: 12672771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Content versus label claims in ephedra-containing dietary supplements.
    Gurley BJ; Gardner SF; Hubbard MA
    Am J Health Syst Pharm; 2000 May; 57(10):963-9. PubMed ID: 10832496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk; final rule.
    Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services
    J Pain Palliat Care Pharmacother; 2004; 18(3):95-107. PubMed ID: 15364637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Feb; 69(28):6787-854. PubMed ID: 14968803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids.
    Haller CA; Benowitz NL
    N Engl J Med; 2000 Dec; 343(25):1833-8. PubMed ID: 11117974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ephedrine alkaloids banned from dietary supplements.
    Thompson CA
    Am J Health Syst Pharm; 2004 Apr; 61(8):750-2, 756. PubMed ID: 15127956
    [No Abstract]   [Full Text] [Related]  

  • 8. Multi-ingredient, caffeine-containing dietary supplements: history, safety, and efficacy.
    Gurley BJ; Steelman SC; Thomas SL
    Clin Ther; 2015 Feb; 37(2):275-301. PubMed ID: 25262198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Online Marketing of
    Lai S; Yu C; Dennehy CE; Tsourounis C; Lee KP
    J Altern Complement Med; 2021 Sep; 27(9):796-802. PubMed ID: 33979529
    [No Abstract]   [Full Text] [Related]  

  • 10. Ephedra and ephedrine for weight loss and athletic performance enhancement: clinical efficacy and side effects.
    Shekelle P; Hardy ML; Morton SC; Maglione M; Suttorp M; Roth E; Jungvig L; Mojica WA; Gagné J; Rhodes S; McKinnon E
    Evid Rep Technol Assess (Summ); 2003 Mar; (76):1-4. PubMed ID: 12647510
    [No Abstract]   [Full Text] [Related]  

  • 11. Ephedrine Alkaloids-Free Ephedra Herb Extract, EFE, Has No Adverse Effects Such as Excitation, Insomnia, and Arrhythmias.
    Takemoto H; Takahashi J; Hyuga S; Odaguchi H; Uchiyama N; Maruyama T; Yamashita T; Hyuga M; Oshima N; Amakura Y; Hakamatsuka T; Goda Y; Hanawa T; Kobayashi Y
    Biol Pharm Bull; 2018; 41(2):247-253. PubMed ID: 29386484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ephedrine-type alkaloid content of nutritional supplements containing Ephedra sinica (Ma-huang) as determined by high performance liquid chromatography.
    Gurley BJ; Wang P; Gardner SF
    J Pharm Sci; 1998 Dec; 87(12):1547-53. PubMed ID: 10189265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements.
    Haller CA; Duan M; Benowitz NL; Jacob P
    J Anal Toxicol; 2004 Apr; 28(3):145-51. PubMed ID: 15107143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA v. ephedra: is it time to lift the ban?
    Pyle KR
    Food Drug Law J; 2006; 61(4):701-51. PubMed ID: 17180770
    [No Abstract]   [Full Text] [Related]  

  • 15. Ephedra in perspective--a current review.
    Abourashed EA; El-Alfy AT; Khan IA; Walker L
    Phytother Res; 2003 Aug; 17(7):703-12. PubMed ID: 12916063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ephedra ban: no shortage of reasons.
    Rados C
    FDA Consum; 2004; 38(2):6-7. PubMed ID: 15101356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects.
    Magkos F; Kavouras SA
    Sports Med; 2004; 34(13):871-89. PubMed ID: 15487903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chiral gas chromatographic determination of ephedrine-type alkaloids in dietary supplements containing Má Huáng.
    Betz JM; Gay ML; Mossoba MM; Adams S; Portz BS
    J AOAC Int; 1997; 80(2):303-15. PubMed ID: 9086588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Supplement use in the adolescent athlete.
    DesJardins M
    Curr Sports Med Rep; 2002 Dec; 1(6):369-73. PubMed ID: 12831686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of ephedra alkaloid and caffeine concentrations in dietary supplements and biological fluids.
    Jacob P; Haller CA; Duan M; Yu L; Peng M; Benowitz NL
    J Anal Toxicol; 2004 Apr; 28(3):152-9. PubMed ID: 15107144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.